Modality
Cell Therapy
MOA
BiTE
Target
BET
Pathway
Notch
DLBCL
Development Pipeline
Preclinical
~Sep 2023
→ ~Dec 2024
Phase 1
Mar 2025
→ Jan 2030
Phase 1Current
NCT05708823
386 pts·DLBCL
2025-03→2030-01·Completed
386 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-01-213.8y awayPh2 Data· DLBCL
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P1/2
Complet…
Catalysts
Ph2 Data
2030-01-21 · 3.8y away
DLBCL
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05708823 | Phase 1/2 | DLBCL | Completed | 386 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET |